| Literature DB >> 32577578 |
Jin Won Lee1,2, Ashish Ranjan Sharma3, Sang-Soo Lee3, Wan Joo Chun2, Hae Sung Kim1.
Abstract
The aim of this study was to evaluate the preoperative C-reactive protein (CRP) to albumin ratio (CAR) of patients with gastric cancer and to investigate the factors correlated with perioperative complications. From March 2016 to December 2019, 128 patients who underwent curative gastrectomy for gastric cancer were enrolled in a retrospective study. The preoperative cutoff value of the CAR for predicting postoperative complications was 0.265 on receiver operating characteristic (ROC) curve analysis. Clinical characteristics were compared between patients with complications (Clavien-Dindo grade ≥2, n = 20) and without complications (Clavien-Dindo grade <2, n = 108). On univariate and multivariate analyses, estimated blood loss (EBL) during the operation (HR 1.003, p = 0.039) and CAR (HR 2.832, p = 0.045) were independent predictors of postoperative complications. In conclusion, preoperative CAR appears to be a predictor of postoperative complications in the patients undergoing surgical treatment of gastric cancer.Entities:
Keywords: C-reactive protein to albumin ratio; Clinical research; Gastric cancer; Gastrointestinal system; Immunology; Oncology; Pathology; Postoperative complication; Surgery
Year: 2020 PMID: 32577578 PMCID: PMC7303550 DOI: 10.1016/j.heliyon.2020.e04220
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Patients' clinicopathological characteristics.
| Number | 128 |
| Age (years) | 66.8 ± 11.69 |
| ≤60 | 39 (30.5) |
| >60 | 89 (69.5) |
| Sex | |
| Male | 91 (71.1) |
| Female | 37 (28.9) |
| BMI(kg/m2) | 24.12 ± 3.86 |
| ≤25 kg/m2 | 77 (60.2) |
| >25 kg/m2 | 51 (39.8) |
| ECOG PS | |
| 0 | 81 (63.3) |
| 1 | 42 (32.8) |
| 2 | 5 (3.9) |
| Hypertension | |
| No | 80 (62.5) |
| Yes | 48 (37.5) |
| DM | |
| No | 95 (74.2) |
| Yes | 33 (25.8) |
| Cardiovascular disease | |
| No | 112 (87.5) |
| Yes | 16 (12.5) |
| CEA (ng/mL) | 3.94 ± 5.54 |
| CA 19-9(U/mL) | 56.86 ± 334.56 |
| Preoperative CRP (mg/dL) | 7.9 ± 21.75 |
| Preoperative Albumin (g/dL) | 4.07 ± 0.51 |
| CAR | 2.41 ± 7.97 |
| ≤0.265 | 74 (57.8) |
| >0.265 | 54 (42.2) |
| mGPS | |
| 0 | 80 (62.5) |
| 1 | 38 (29.7) |
| 2 | 10 (7.8) |
| Operation time (min) | 167.26 ± 52.95 |
| EBL (mL) | 113.28 ± 129.35 |
| Operation Approach | |
| Open | 54 (42.2) |
| Laparoscopic assisted | 2 (1.6) |
| Totally laparosopic | 68 (53.1) |
| Robotic | 4 (3.1) |
| Extent of Resection | |
| TG | 28 (21.9) |
| STG | 97 (75.8) |
| PG | 2 (1.6) |
| Whipple's procedure | 1 (0.8) |
| LN dissection | |
| D1+ | 85 (66.4) |
| D2 | 43 (33.6) |
| Type of Reconstruction | |
| Billroth I | 3 (2.4) |
| Billroth II | 95 (74.2) |
| Roux-en-Y | 28 (21.9) |
| Double Tract | 2 (1.55) |
| Tumor size (cm) | 3.68 ± 3.05 |
| Harvested LN | 29.81 ± 16.45 |
| Metastatic LN | 2.92 ± 8.69 |
| AJCC 7th Stage | |
| I | 74 (57.8) |
| II | 20 (15.6) |
| III | 34 (26.6) |
| Length of hospital stay | 16.48 ± 8.3 |
| Length of postoperative hospital stay | 11.71 ± 7.13 |
| Complication | |
| < CDC grade II | 108 (84.4) |
| ≥ CDC grade II | 20 (15.6) |
| Grade of Complication | |
| No complication | 106 (82.8) |
| CDC grade I | 2 (1.6) |
| CDC grade II | 15 (11.7) |
| CDC grade IIIA | 1 (0.8) |
| CDC grade IIIB | 4 (3.1) |
| Name of Complication | |
| Pneumonia | 6 (4.7) |
| Bleeding | 1 (0.8) |
| Intestinal obstruction | 1 (0.8) |
| Pancreatic fistula | 1 (0.8) |
| Intraabdominal abscess | 3 (2.3) |
| Wound infection | 3 (2.3) |
| A-loop syndrome | 1 (0.8) |
| Gastric stasis | 3 (2.3) |
| Cerebral infarction | 2 (1.6) |
| Delirium | 1 (0.8) |
Data are n (%) or means ± standard devation.
BMI body mass index, ECOG PS esteran cooperative oncology group performance status, DM diabetes mellitus, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, CAR C-reactive protein to albumin ratio, mGPS modified Glasgow prognostic score EBL estimated blood loss, TG total gastrectomy, STG subtotal gastrectomy, PG proximal gastectomy LN lymph node, AJCC American joint committee on cancer, CDC Clavian-Dindo classification, A-loop afferent loop.
Comparison of clinical characteristics between patients with and without postoperative complications.
| Clavien-Dindo grade<2 | Clavien-Dindo grade≥2 | ||
|---|---|---|---|
| Age | 0.611 | ||
| ≤60 | 34 (87.2) | 5 (12.8) | |
| >60 | 74 (83.1) | 15 (16.9) | |
| Sex | 0.792 | ||
| Male | 76 (83.5) | 15 (16.5) | |
| Female | 32 (86.5) | 5 (13.5) | |
| BMI(kg/m2) | 24.38 ± 3.91 | 22.70 ± 3.30 | 0.073 |
| BMI(kg/m2) | 0.213 | ||
| ≤25 | 62 (80.5) | 15 (19.5) | |
| >25 | 46 (90.2) | 5 (9.8) | |
| ECOG PS | 0.272 | ||
| 0 | 70 (86.4) | 11 (13.6) | |
| 1 | 35 (83.3) | 7 (16.7) | |
| 2 | 2 (60.0) | 2 (40.0) | |
| Hypertension | 1.000 | ||
| No | 67 (83.8) | 13 (16.) | |
| Yes | 41 (85.4) | 7 (14.6) | |
| DM | 0.781 | ||
| No | 81 (85.3) | 14 (14.7) | |
| Yes | 27 (81.8) | 6 (18.2) | |
| Cardiovascular disease | 1.000 | ||
| No | 95 (84.8) | 17 (15.2) | |
| Yes | 13 (81.3) | 3 (18.8) | |
| CEA (ng/mL) | 4.01 ± 5.90 | 3.6 ± 2.94 | 0.782 |
| CA 19-9(U/mL) | 52.68 ± 352.35 | 81.6 ± 205.03 | 0.750 |
| CRP (mg/dL) | 5.12 ± 8.86 | 8.42 ± 23.36 | 0.536 |
| Albumin (g/dL) | 4.12 ± 0.52 | 3.84 ± 0.41 | 0.028 |
| CAR | 0.029 | ||
| ≤0.265 | 67 (90.5) | 7 (9.5) | |
| >0.265 | 41 (75.9) | 13 (24.1) | |
| mGPS | 0.186 | ||
| 0 | 71 (88.8) | 9 (11.3) | |
| 1 | 29 (76.3) | 9 (23.7) | |
| 2 | 8 (80) | 2 (20) | |
| Operation time (min) | 165 ± 51.35 | 179 ± 60.89 | 0.262 |
| EBL (mL) | 101.29 ± 118.11 | 178.0 ± 167.5 | 0.014 |
| Approach | 0.529 | ||
| Open | 43 (79.6) | 11 (20.4) | |
| Lap Assisted | 2 (100) | 0 (0) | |
| Totall Lap | 60 (88.2) | 8 (11.8) | |
| Robotic | 3 (75.0) | 1 (25.0) | |
| Extent of Resection | 0.350 | ||
| TG | 21 (75.0) | 7 (25.0) | |
| STG | 84 (86.6) | 13 (13.4) | |
| PG | 2 (100) | 0 (0) | |
| Whipple | 1 (100) | 0 (0) | |
| LN dissection | 1.000 | ||
| D1+ | 72 (84.7) | 13 (15.3) | |
| D2 | 36 (83.7) | 7 (16.3) | |
| Type of Reconstruction | 0.379 | ||
| Billroth I | 3 (100) | 0 (0) | |
| Billroth II | 82 (86.3) | 13 (13.7) | |
| Roux-en-Y | 21 (75.0) | 7 (25.0) | |
| Double Tract | 2 (100) | 0 (0) | |
| Tumor size (cm) | 3.67 ± 3.16 | 3.72 ± 2.50 | 0.945 |
| Harvested LN | 29.85 ± 17.06 | 29.60 ± 13.09 | 0.950 |
| Metatatic LN | 3.25 ± 9.39 | 1.15 ± 1.87 | 0.323 |
| AJCC 7th Stage | 0.152 | ||
| I | 65 (87.8) | 9 (12.2) | |
| II | 14 (70.0) | 6 (30.0) | |
| III | 29 (85.3) | 5 (14.7) | |
| Length of hospital stay | 14.69 ± 4.97 | 26.15 ± 14.33 | 0.000 |
| Postoperative hospital stay | 10.21 ± 3.83 | 19.80 ± 13.24 | 0.000 |
Data are n (%) or means ± standard deviation.
BMI body mass index, ECOG PS esteran cooperative oncology group performance status, DM diabetes mellitus, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, CAR C-reactive protein to albumin ratio, mGPS modified Glasgow prognostic score, EBL estimated blood loss, TG total gastrectomy, STG subtotal gastrectomy, PG proximal gastectomy LN lymph node, AJCC American Joint Committee on Cancer.
Multivariate analysis for PCs.
| HR | 95% CI | ||
|---|---|---|---|
| CAR | 0.045 | ||
| ≤0.265 | 1 | ||
| >.265 | 2.832 | 1.023–7.841 | |
| EBL (mL) | 1.003 | 1.000–1.006 | 0.039 |
HR hazard ratio, CI confidence interval, CAR C-reactive protein to albumin ratio, EBL estimated blood loss.